Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S65-70. doi: 10.1016/j.clml.2014.06.011.

Biology and treatment of myeloma.

Author information

1
Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom; Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy.
2
Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom.
3
Centre for Myeloma Research, Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom. Electronic address: gareth.morgan@icr.ac.uk.

Abstract

In recent years significant progress has been made in the understanding of multiple myeloma (MM) biology and its treatment. Current strategies for the treatment of MM involve the concept of sequential blocks of therapy given as an induction followed by consolidation and maintenance. In an age characterized by emerging and more powerful laboratory techniques, it is of primary importance to understand the biology of MM and how this biology can guide the development of new treatment strategies. This review focuses on the genetic basis of myeloma, including the most common genetic abnormalities and pathways affected and the effects that these have on MM treatment strategies. MM biology is discussed also in the light of more recent theory of intraclonal heterogeneity.

KEYWORDS:

Genetic; Intraclonal heterogeneity; Multiple myeloma; Sequential treatment; Treatment

PMID:
25486959
DOI:
10.1016/j.clml.2014.06.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center